118 related articles for article (PubMed ID: 23722251)
1. Virological failure and drug resistance during first line anti-retroviral treatment in Indonesia.
Fibriani A; Wisaksana R; Indrati A; Hartantri Y; van de Vijver D; Schutten M; Alisjahbana B; Sudjana P; Boucher CA; van Crevel R; van der Ven A
J Med Virol; 2013 Aug; 85(8):1394-401. PubMed ID: 23722251
[TBL] [Abstract][Full Text] [Related]
2. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
4. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
[TBL] [Abstract][Full Text] [Related]
6. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
7. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
[TBL] [Abstract][Full Text] [Related]
8. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
[TBL] [Abstract][Full Text] [Related]
9. Prospective long-term outcomes of a cohort of Ugandan children with laboratory monitoring during antiretroviral therapy.
Kekitiinwa A; Asiimwe AR; Kasirye P; Korutaro V; Kitaka S; Maganda A; Madalon M; Graziano FM
Pediatr Infect Dis J; 2012 Aug; 31(8):e117-25. PubMed ID: 22581223
[TBL] [Abstract][Full Text] [Related]
10. Virological Suppression and Patterns of Resistance Amongst Patients on Antiretroviral Therapy at 4 Nigerian Military Hospitals.
Babajide K; Ayemoba O; Terfa K; Ake J; Crowell TA; Adamu Y; Mohammed T; Okoye I; Odeyemi S; Crawford K; Hughes L; Akintunde E; Umar T; Hamm TE; Njoku OS
Curr HIV Res; 2017; 15(2):146-151. PubMed ID: 28521719
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
12. Determinants of virological failure and antiretroviral drug resistance in Mozambique.
Rupérez M; Pou C; Maculuve S; Cedeño S; Luis L; Rodríguez J; Letang E; Moltó J; Macete E; Clotet B; Alonso P; Menéndez C; Naniche D; Paredes R
J Antimicrob Chemother; 2015 Sep; 70(9):2639-47. PubMed ID: 26084302
[TBL] [Abstract][Full Text] [Related]
13. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
14. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
15. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
17. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
18. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure.
Lwembe R; Ochieng W; Panikulam A; Mongoina CO; Palakudy T; Koizumi Y; Kageyama S; Yamamoto N; Shioda T; Musoke R; Owens M; Songok EM; Okoth FA; Ichimura H
J Med Virol; 2007 Jul; 79(7):865-72. PubMed ID: 17516531
[TBL] [Abstract][Full Text] [Related]
19. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults.
Hawkins C; Ulenga N; Liu E; Aboud S; Mugusi F; Chalamilla G; Sando D; Aris E; Carpenter D; Fawzi W
J Antimicrob Chemother; 2016 Jul; 71(7):1966-74. PubMed ID: 27076106
[TBL] [Abstract][Full Text] [Related]
20. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.
Alvarez-Uria G; Naik PK; Pakam R; Midde M
Trop Med Int Health; 2012 Sep; 17(9):1152-5. PubMed ID: 22487689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
